Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection

AAPS Journal

Volumn 14, Issue 3, 2012, Pages 571-580

  Jin, Runyan ^a   Fossler, Michael J ^b   McHutchison, John G ^c   Howell, Charles D ^d   Dowling, Thomas C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

hepatitis C; pharmacodynamics; population pharmacokinetics; ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; APPARENT CENTRAL VOLUME; APPARENT INTERCOMPARTMENTAL CLEARANCE; APPARENT ORAL CLEARANCE; APPARENT PERIPHERAL VOLUME; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHRONIC HEPATITIS; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACODYNAMICS; PHARMACOKINETICS; POPULATION PHARMACODYNAMICS; POPULATION PHARMACOKINETICS; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 84862730244     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9368-z     Document Type: Article

References (33)

1. GL Armstrong A Wasley EP Simard GM McQuillan WL Kuhnert MJ Alter 2006 The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 705 714 16702586
2. P Marcellin T Asselah N Boyer 2002 Fibrosis and disease progression in hepatitis C Hepatology 36 S47 S56 12407576 10.1002/hep.1840360707
3. LM Blatt MG Mutchnick MJ Tong, et al. 2000 Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States J Viral Hepat. 7 196 202 10849261 10.1046/j.1365-2893.2000.00221.x 1:STN:280:DC%2BD3czgsl2hsA%3D%3D
4. OV Nainan MJ Alter D Kruszon-Moran, et al. 2006 Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States Gastroenterology 131 478 484 16890602 10.1053/j.gastro.2006.06.007 1:CAS:528:DC%2BD28XpsFyksL0%3D
5. MG Ghany DB Strader DL Thomas LB Seeff American Association for the Study of Liver Diseases 2009 Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 1335 1374 19330875 10.1002/hep.22759 1:CAS:528: DC%2BD1MXkslWjs7o%3D
6. T Poynard P Marcellin SS Lee, et al. 1998 Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1426 1432 9807989 10.1016/S0140-6736(98)07124-4 1:CAS:528:DyaK1cXnsVSmsLg%3D
7. O Reichard G Norkrans A Fryden JH Braconier A Sonnerborg O Weiland 1998 Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group Lancet 351 83 87 9439491 10.1016/S0140-6736(97)06088-1 1:CAS:528:DyaK1cXmsFSqtw%3D%3D
8. G Scotto F Campanozzi A D'Adduzio M Grimaldi V Fazio 2003 Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis C patients infected by genotype 1b BioDrugs 17 281 286 12899645 10.2165/00063030-200317040-00007 1:CAS:528: DC%2BD3sXntlKis7k%3D
9. HS Conjeevaram MW Fried LJ Jeffers, et al. 2006 Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 470 477 16890601 10.1053/j.gastro.2006.06.008 1:CAS:528:DC%2BD28XpsFyksL4%3D
10. LJ Jeffers W Cassidy CD Howell S Hu KR Reddy 2004 Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 Hepatology 39 1702 1708 15185312 10.1002/hep.20212 1:CAS:528: DC%2BD2cXlsVWrtrc%3D
11. AJ Muir JD Bornstein PG Killenberg Atlantic Coast Hepatitis Treatment Group 2004 Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 350 2265 2271 15163776 10.1056/NEJMoa032502 1:CAS:528:DC%2BD2cXksVehtr4%3D
12. CD Howell TC Dowling M Paul, et al. 2008 Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection Clin Gastroenterol Hepatol 6 575 583 18407798 10.1016/j.cgh.2008.02.035 1:CAS:528:DC%2BD1cXmvVersL0%3D
13. N Bräu EJ Bini S Currie, et al. 2006 Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin J Viral Hepat. 13 4 242 249 16611190 10.1111/j.1365-2893.2005.00682.x
14. Y Liu C Xu R Yan C Lim LT Yeh CC Lin 2006 Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma J Chromatogr B Analyt Technol Biomed Life Sci. 832 17 23 16455313 10.1016/j.jchromb.2005.12.034 1:CAS:528:DC%2BD28Xhtlartrs%3D
15. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 1244564 10.1159/000180580 1:STN:280: DyaE28%2FnsF2isw%3D%3D
16. DJ Lunn N Best A Thomas J Wakefield D Spiegelhalter 2002 Bayesian analysis of population PK/PD models: general concepts and software J Pharmacokinet Pharmacodyn 29 271 307 12449499 10.1023/A:1020206907668 1:CAS:528:DC%2BD38XntFGrt7w%3D
17. A Thomas B O'Hara U Ligges S Sturtz 2009 Making BUGS open R News 6 12 17
18. M Romero-Gomez M Del Mar Viloria RJ Andrade, et al. 2005 Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 3 636 641 15765399 10.1053/j.gastro.2004.12.049 1:CAS:528:DC%2BD2MXivFWntL8%3D
19. DJ Spiegelhalter NG Best 2003 Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling Stat Med. 22 3687 3709 14652869 10.1002/sim.1586
20. WD Dupont WD Plummer Jr 1998 Power and sample size calculations for studies involving linear regression Control Clin Trials 19 589 601 9875838 10.1016/S0197-2456(98)00037-3 1:STN:280:DyaK1M%2FptFSnsA%3D%3D
21. B Brennan R Morrison CH Hagedorn, et al. 2005 Effect of ethnicity on the pharmacokinetics of peginterferon alfa-2a (40 KD) and ribavirin in patients with chronic hepatitis C Hepatology 42 652A 10.1016/j.jhep.2004.11.044 (abstract)
22. JF Jen P Glue S Gupta D Zambas G Hajian 2000 Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C Ther Drug Monit. 22 555 565 11034261 10.1097/00007691-200010000-00010 1:CAS:528:DC%2BD3cXnt1Kmtr4%3D
23. JR Wade E Snoeck F Duff M Lamb K Jorga 2006 Pharmacokinetics of ribavirin in patients with hepatitis C virus Br J Clin Pharmacol 62 710 714 17118126 10.1111/j.1365-2125.2006.02704.x 1:CAS:528:DC%2BD2sXktlaqsg%3D%3D
24. A Bruchfeld K Lindahl R Schvarcz L Stahle 2002 Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis Ther Drug Monit. 24 701 708 12451285 10.1097/00007691-200212000-00004 1:CAS:528:DC%2BD38XptVSitLc%3D
25. N Kamar E Chatelut E Manolis T Lafont J Izopet L Rostaing 2004 Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function Am J Kidney Dis. 43 140 146 14712437 10.1053/j.ajkd.2003.09.019 1:CAS:528:DC%2BD2cXht1egsrY%3D
26. M Gusella F Pasini C Bolzonella, et al. 2011 Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumors Br J Clin Pharmacol 71 437 444 21284703 10.1111/j.1365-2125.2010.03838.x 1:CAS:528:DC%2BC3MXjvFSmsr0%3D
27. P Glue 1999 The clinical pharmacology of ribavirin Semin Liver Dis. 19 Suppl 1 17 24 10349689 1:CAS:528:DyaK1MXjsFensb8%3D
28. L Li SH Koo LM Limenta, et al. 2009 Effect of dietary purines on the pharmacokinetics of orally administered ribavirin J Clin Pharmacol 49 661 667 19369574 10.1177/0091270009335002 1:CAS:528:DC%2BD1MXmvVOrurw%3D
29. Thompson AJ, Patel K, Chuang WL, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2011. doi: 10.1136/gut.2010.236158.
30. Tillmann HL, Patel K, Muir AJ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011. doi: 10.1016/j.jhep.2011.03.015.
31. Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 2011. doi: 10.1002/hep.24458.
32. V Loustaud-Ratti S Alain A Rousseau, et al. 2008 Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C Hepatology 47 5 1453 1461 18435468 10.1002/hep.22217 1:CAS:528:DC%2BD1cXmvVCiu7w%3D
33. E Snoeck JR Wade F Duff, et al. 2006 Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD) plus ribavirin Br J Clin Pharmacol 62 6 699 709 17118125 10.1111/j.1365-2125.2006.02741.x 1:CAS:528:DC%2BD2sXktlaruw%3D%3D